Early Access of TMC207 in Combination With Other Anti-Tuberculosis (TB) Drugs in Subjects With Extensively Drug Resistant (XDR) or Pre-XDR Pulmonary Tuberculosis (TB)

Trial Profile

Early Access of TMC207 in Combination With Other Anti-Tuberculosis (TB) Drugs in Subjects With Extensively Drug Resistant (XDR) or Pre-XDR Pulmonary Tuberculosis (TB)

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Feb 2017

At a glance

  • Drugs Bedaquiline (Primary) ; Antibacterials
  • Indications Pulmonary tuberculosis
  • Focus Expanded access; Therapeutic Use
  • Sponsors Janssen Infectious Diseases BVBA
  • Most Recent Events

    • 08 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 21 Aug 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 17 Mar 2012 Planned end date changed from 1 Oct 2014 to 16 Nov 2016 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top